Alternative medicines need to be considered in diabetes management

Jul 04, 2007

People with diabetes are risking their health by not discussing their use of complementary and alternative therapies with the health professionals managing their conventional treatment.

A review of the international health literature has shown nutritional supplements and herbal medicines are the most commonly used complementary and alternative therapies in diabetes.

Annie Chang, a PhD candidate in Griffith’s School of Nursing, said while some products may have benefits for patients, they can also have side effects in their own right or interact with conventional medications.

“Fenugreek for example, used as a supplement, may affect blood sugar levels but patients are already on other blood sugar lowering medications as well.”

While the prevalence of use varies widely between different countries (17-72%), her review suggests nearly half of people living with diabetes supplement their conventional medicines with some form of alternative therapy.

Women, over 65-year-olds, those who had been living with diabetes for longer, and people interested in self management of their condition were the most likely to use alternative therapies.

“People will tell their alternative practitioners that they are using Western medicines but the vast majority will not discuss their alternative therapies with a doctor or other healthcare professional,” she said.

Ms Chang, who has also surveyed more than 300 diabetics in Taiwan, said people feared their doctor would not be interested in discussing alternative medicines or that they might ‘get into trouble’ for taking them.

“The evidence is that patients are using these products and may even reduce their conventional medicine doses and modify the timing of doses so they aren’t taking both together.”

“While it might be impossible for Western medicine to learn all about complementary and alternative therapies, healthcare professionals do need to be included in discussions about them so we can document their use and be aware of any potential problems for our patients.”

Source: Research Australia

Explore further: Early bottlenecks in developing biopharmaceutical products delay commercialization

add to favorites email to friend print save as pdf

Related Stories

MRI for a quantum simulation

Jul 31, 2014

Magnetic resonance imaging (MRI), which is the medical application of nuclear magnetic resonance spectroscopy, is a powerful diagnostic tool. MRI works by resonantly exciting hydrogen atoms and measuring ...

Making progress on deforestation

Jun 24, 2014

In 2005, Brazil was losing more forest each year than any other country. The good news is that today, Brazil has reduced deforestation in the Amazon rainforest by 70 percent, according to a recent study. ...

Romania keeps ancient tradition of bee medicine alive

Apr 10, 2014

Bee venom to combat multiple sclerosis, pollen for indigestion, honey to heal wounds—the humble bee has been a key source of alternative medicines since ancient times, and Romania is working to keep the ...

Recommended for you

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

Aug 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments : 0